收费全文 | 1476篇 |
免费 | 161篇 |
国内免费 | 68篇 |
耳鼻咽喉 | 1篇 |
儿科学 | 20篇 |
妇产科学 | 2篇 |
基础医学 | 29篇 |
口腔科学 | 4篇 |
临床医学 | 103篇 |
内科学 | 76篇 |
皮肤病学 | 4篇 |
神经病学 | 32篇 |
特种医学 | 80篇 |
外科学 | 44篇 |
综合类 | 83篇 |
预防医学 | 25篇 |
眼科学 | 6篇 |
药学 | 998篇 |
中国医学 | 159篇 |
肿瘤学 | 39篇 |
2023年 | 26篇 |
2022年 | 21篇 |
2021年 | 51篇 |
2020年 | 50篇 |
2019年 | 85篇 |
2018年 | 60篇 |
2017年 | 67篇 |
2016年 | 62篇 |
2015年 | 59篇 |
2014年 | 88篇 |
2013年 | 158篇 |
2012年 | 84篇 |
2011年 | 75篇 |
2010年 | 56篇 |
2009年 | 51篇 |
2008年 | 61篇 |
2007年 | 62篇 |
2006年 | 58篇 |
2005年 | 51篇 |
2004年 | 49篇 |
2003年 | 38篇 |
2002年 | 34篇 |
2001年 | 28篇 |
2000年 | 23篇 |
1999年 | 31篇 |
1998年 | 14篇 |
1997年 | 24篇 |
1996年 | 26篇 |
1995年 | 20篇 |
1994年 | 25篇 |
1993年 | 15篇 |
1992年 | 16篇 |
1991年 | 14篇 |
1990年 | 15篇 |
1989年 | 15篇 |
1988年 | 5篇 |
1987年 | 6篇 |
1986年 | 9篇 |
1985年 | 7篇 |
1984年 | 8篇 |
1983年 | 4篇 |
1982年 | 10篇 |
1981年 | 8篇 |
1980年 | 8篇 |
1979年 | 8篇 |
1978年 | 4篇 |
1977年 | 2篇 |
1976年 | 4篇 |
1975年 | 3篇 |
1973年 | 6篇 |
Areas covered: An unprecedented level of research activity involving multiple approaches is seeking to improve tuberculosis treatment. This report is a review of the quantitative methods currently used on clinical data sets to identify drug exposure targets and optimal drug combinations for tuberculosis treatment. A high-level summary of the methods, including the strengths and weaknesses of each method and potential methodological improvements is presented. Methods incorporating data generated from multiple sources such as in vitro and clinical studies, and their potential to provide better estimates of pharmacokinetic/pharmacodynamic (PK/PD) targets, are discussed. PK/PD relationships identified are compared between different studies and data analysis methods.
Expert opinion: The relationships between drug exposures and tuberculosis treatment outcomes are complex and require analytical methods capable of handling the multidimensional nature of the relationships. The choice of a method is guided by its complexity, interpretability of results, and type of data available. 相似文献
2. To assess the potential for inadequate coverage for these two AO enzyme-mediated metabolites in nonclinical safety studies, given concerns due to differences in AO enzymes expression between preclinical species and humans, the human circulating levels of the two AO enzyme-mediated metabolites were predicted prospectively using in vitro and in vivo models. Both formation clearance and elimination clearance of the two metabolites were predicted based on in vitro to in vivo correlation and comparison with in vivo data from rats.
3. The result showed that the 4-OH metabolite of Compound A would account for less than 3% of the total drug-related exposure in human plasma, while the exposure to the 2-oxo metabolite would be relatively high (~70%).
4. The predicted human exposure levels for the two metabolites are in similar ranges as those observed in monkeys. These data taken together support the advancement to clinical development of Compound A. 相似文献